Soft drusen in rhesus macaques as a nonhuman primate model of early age-related macular degeneration
恒河猴的软玻璃疣作为早期年龄相关性黄斑变性的非人类灵长类动物模型
基本信息
- 批准号:10547804
- 负责人:
- 金额:$ 68.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AgeAge related macular degenerationAnimal ModelAnimalsApolipoprotein EApolipoproteinsApolipoproteins BArterial Fatty StreakBindingBioinformaticsBlindnessBody WeightBody Weights and MeasuresBody fatCaliforniaCardiovascular DiseasesCellsCholesterolCholesterol EstersChoroidComplementComplement Membrane Attack ComplexContralateralDepositionDevelopmentDietDietary FatsDoseDrusenElderlyEpidemiologyEuthanasiaEvolutionExposure toEyeFastingFatty acid glycerol estersFundusGene ExpressionGene Expression ProfileGenesGeneticGenetic Predisposition to DiseaseGlial Fibrillary Acidic ProteinGoalsGrowthHealthHeterogeneityHigh Density LipoproteinsHigh Fat DietHistologicHumanHydroxymethylglutaryl-CoA Reductase InhibitorsImageImaging technologyImmuneImmunohistochemistryInflammatory ResponseInterventionLaboratory AnimalsLipidsLipofuscinLipoproteinsLow-Density LipoproteinsMacacaMacaca mulattaMacrophage ActivationMammalsMeasuresMetabolicModelingMolecularMultimodal ImagingNational Institute on AgingOilsOptical Coherence TomographyOralPathogenesisPathway interactionsPatientsPhenotypePilot ProjectsPlacebosPlasmaPrevalencePrimatesResearchResolutionRetinaRisk FactorsRoleSerumSimvastatinSmokingStructure of retinal pigment epitheliumSurveysSusceptibility GeneTestingTissuesTransferaseTriglyceridesagedatorvastatincohortcostdietarygenetic variantgenome sequencinghepatic lipaseimaging capabilitiesin vivoin vivo imaginginsightlipid metabolismlipoprotein lipasemRNA Expressionmacrogliamaculamultimodalitynew therapeutic targetnext generation sequencingnonhuman primatenovel therapeuticsophthalmic examinationoxidationprogramsrecruitserial imagingsexsingle-cell RNA sequencingsugartherapy developmenttranslational studywhole genome
项目摘要
PROJECT SUMMARY
Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly, but current treatments
target advanced stages when interventions may be limited by irreversible cell loss. Soft drusen are the initial and
hallmark feature of AMD, but their pathogenesis is unclear and the development of treatments is limited by the
lack of good animal models. Unlike most laboratory animals, nonhuman primates (NHPs) possess a true macula
and spontaneously develop soft drusen resembling early human AMD. Prior studies of NHP drusen have been
observational, cross-sectional, and qualitative, owing to the high costs of maintaining aged animals, limited
longitudinal imaging capabilities, and lack of Next-Generation Sequencing (NGS) and bioinformatics support.
We recently surveyed a unique colony of geriatric rhesus macaques at the California National Primate Research
Center (CNPRC), and found a 30.6% prevalence of drusen. Using high-resolution multimodal in vivo imaging,
we precisely measured drusen progression over 2 years, with histological and ultrastructural correlates
demonstrating lipid accumulation resembling human soft drusen. Similar to cardiovascular diseases, AMD share
epidemiologic risk factors such as high fat diets, susceptibility genes in lipid metabolism, and deposits similar to
atherosclerotic plaques with lipoprotein accumulation, lipid oxidation, and complement-based inflammatory
responses. Recent pilot studies suggest that high-dose oral atorvastatin can cause drusen regression in some
AMD patients, but human studies are limited by the heterogeneity of AMD phenotypes and variability in subject
diets and serum lipid concentrations.
In this study, we plan to establish a new, unique cohort of aged rhesus macaques with soft drusen, and perform
1) detailed ophthalmic characterization using spectral-domain optical coherence tomography (SD-OCT) to
precisely measure retinal layers and track drusen volume, and fundus autofluorescence (FAF) to measure RPE
lipofuscin, 2) metabolic profiling to measure fasting plasma metabolites, lipoproteins, and apolipoproteins, and
3) whole-genome sequencing to identify genetic variants in animals with drusen that may be shared with human
AMD. Next, we will establish the impact of a “Western-style” high-fat/sugar (HFS) diet and high-dose atorvastatin
on drusen progression and RPE health over 2 years, and determine possible correlations with dietary fats and
serum lipids. Finally, we will employ NGS-based single-cell RNA-sequencing (scRNA-Seq) to determine the
gene expression profile in macular RPE cells with and without soft drusen, exposure to HFS diet, or treatment
with high-dose statin, followed by immunohistochemistry of contralateral eyes to evaluate and validate identified
gene sets or pathways, as well as complement and other immune pathways. Together, these studies will not
only establish a highly-valuable and unique cohort of aged rhesus macaques with soft drusen suitable for
translational studies, but also explore the role of dietary lipids, oral statins, RPE gene expression, and immune
pathways in this NHP model of early AMD.
项目概要
年龄相关性黄斑变性(AMD)是老年人视力丧失的主要原因,但目前的治疗方法
针对晚期阶段,此时干预措施可能会受到不可逆细胞损失的限制。
AMD 的标志性特征,但其发病机制尚不清楚,并且治疗方法的开发受到
与大多数实验动物不同,非人类灵长类动物(NHP)拥有真正的黄斑。
并自发地形成软玻璃膜疣,重新组装早期人类 AMD 的先前研究已被报道。
观察性的、横截面的和定性的,由于维持老年动物的高成本而受到限制,有限
纵向成像能力,缺乏下一代测序(NGS)和生物信息学支持。
我们最近在加州国家灵长类动物研究中心调查了一组独特的老年恒河猴
中心 (CNPRC),使用高分辨率多模态体内成像发现玻璃膜疣的患病率为 30.6%。
我们通过组织学和超微结构的相关性精确测量了两年内玻璃膜疣的进展情况
与心血管疾病相似,AMD 也具有脂质积累重组人类软玻璃膜疣的作用。
流行病学危险因素,如高脂肪饮食、脂质代谢的易感基因以及类似的沉积物
动脉粥样硬化斑块伴有脂蛋白积累、脂质氧化和补体炎症
最近的初步研究表明,高剂量口服阿托伐他汀可以导致某些人的玻璃疣消退。
AMD 患者,但人类研究受到 AMD 表型异质性和受试者变异性的限制
饮食和血清脂质浓度。
在这项研究中,我们计划建立一个新的、独特的患有软玻璃膜疣的老年恒河猴群体,并进行
1) 使用谱域光学相干断层扫描 (SD-OCT) 进行详细的眼科表征
精确测量视网膜层并跟踪玻璃疣体积,并通过眼底自发荧光 (FAF) 测量 RPE
脂褐质,2) 代谢分析以测量空腹血浆代谢物、脂蛋白和载脂蛋白,以及
3) 全基因组测序,以确定患有玻璃膜疣的动物中可能与人类共有的遗传变异
AMD。接下来,我们将确定“西式”高脂肪/糖 (HFS) 饮食和高剂量阿托伐他汀的影响。
2 年来玻璃疣进展和 RPE 健康状况,并确定与膳食脂肪和
最后,我们将采用基于 NGS 的单细胞 RNA 测序 (scRNA-Seq) 来确定
有或没有软玻璃膜疣、暴露于 HFS 饮食或治疗的黄斑 RPE 细胞的基因表达谱
使用高剂量他汀类药物,然后对对侧眼睛进行免疫组织化学分析以评估和验证已识别的
这些研究不会将基因组或途径,以及补体和其他免疫途径结合起来。
只建立一个具有软玻璃膜疣的高价值且独特的老年恒河猴群体,适合
转化研究,还探索膳食脂质、口服他汀类药物、RPE 基因表达和免疫的作用
早期 AMD 的 NHP 模型中的通路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Glenn Yiu其他文献
Glenn Yiu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Glenn Yiu', 18)}}的其他基金
Soft drusen in rhesus macaques as a nonhuman primate model of early age-related macular degeneration
恒河猴的软玻璃疣作为早期年龄相关性黄斑变性的非人类灵长类动物模型
- 批准号:
10322112 - 财政年份:2021
- 资助金额:
$ 68.48万 - 项目类别:
A nanoparticle platform for targeted delivery of therapeutic agents to retinal pigment epithelial or choroidal endothelial cells
用于将治疗剂靶向递送至视网膜色素上皮或脉络膜内皮细胞的纳米颗粒平台
- 批准号:
9195104 - 财政年份:2016
- 资助金额:
$ 68.48万 - 项目类别:
相似国自然基金
HTRA1介导CTRP5调控脂代谢通路在年龄相关性黄斑变性中的致病机制研究
- 批准号:82301231
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ALKBH5通过SHP-1调控视网膜色素上皮细胞铁死亡在年龄相关性黄斑变性中的作用机制研究
- 批准号:82301213
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
视网膜色素上皮细胞中NAD+水解酶SARM1调控自噬溶酶体途径参与年龄相关性黄斑变性的机制研究
- 批准号:82301214
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
GPC1调控JNK/STAT3信号通路在年龄相关性黄斑变性中的作用及机制研究
- 批准号:82301220
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于疾病进展量化评估的年龄相关性黄斑变性个性化智能诊疗决策系统构建研究
- 批准号:82301208
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
In vivo 2-photon imaging of retinal biochemistry before and after retinal organoid transplantation
视网膜类器官移植前后视网膜生物化学的体内2光子成像
- 批准号:
10643273 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
- 批准号:
10726508 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Project 2 - Molecular Imaging of ectopic calcification
项目 2 - 异位钙化的分子成像
- 批准号:
10628929 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Deciphering the role of mitochondrial/autophagy dysfunction in regulating inflammatory processes during AMD pathogenesis
破译线粒体/自噬功能障碍在 AMD 发病机制中调节炎症过程中的作用
- 批准号:
10664118 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Back of the eye drug delivery: Novel contact lenses, pathways, and in-silico modeling
眼后药物输送:新型隐形眼镜、通路和计算机建模
- 批准号:
10735642 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别: